A global phase III, double-blind, randomized trial of BNT327/PM8002 plus chemotherapy (chemo) compared to atezolizumab plus chemo in patients (pts) with first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).

Authors: Martin Reck, John Heymach, Kevin Franks, Carl Michael Gay, Vinod Ganju, Ina Nordman, Ying Cheng, Nicolas Girard, Mehmet Ali Nahit Sendur, Ilhan Celik, Isaac Dai, Secil Koseoglu, Sarita Koride, Qiong Wang, Silke Günther, Guoqiang Hu, Özlem Türeci, Ugur Sahin

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8129

Source: Full article

---

Abstract

TPS8129